This week’s view
According to Meiye observation, on December 8, 2021, Qiao Yadeng under aierjian ® Qualitative face ® （Juvéderm ® VOLBELLA ® With lidocaine) is officially listed in China. This product was approved by the China food and Drug Administration on April 19, 2021, becoming the first and only hyaluronic acid product approved for lip injection in China. It is injected into the lip red body and the lip mucosa, superficial or middle dermis of the lip red edge to correct structural defects such as lip asymmetry, contour deformity and volume defect. According to the Research Report on the exploration of lip beauty market released by ipso, the market capacity of lip beauty demanders is large. At present, among Chinese women aged 20 to 50, more than 50% of consumers believe that there are lip problems and need to improve. Among them, the focus of Chinese consumers on lip problems is to improve moisture (63%), fullness (56%) and fine lines (46%). It is recommended that Imeik Technology Development Co.Ltd(300896) and Bloomage Biotechnology Corporation Limited(688363) pharmaceutical machinery manufacturers who occupy the high gross profit margin of the medical beauty industry chain and have strong R & D strength, as well as Lancy Co.Ltd(002612) downstream institutions of the medical beauty industry chain and Huahan plastic surgery institutions which have the advantages of institutional location, talent system and academic platform and collect certain famous medical resources.
Market performance
This week, the retail trade (CITIC) index closed at 4059.70, up 0.88%, up 1.15% since the beginning of the year, and the performance of the sector underperformed Shanghai and Shenzhen 300.
Company announcement
[ Imeik Technology Development Co.Ltd(300896) : Announcement on the reduction of shares by shareholders holding more than 5% to 1%]
[ Lancy Co.Ltd(002612) : announcement of the resolution of the ninth extraordinary general meeting of shareholders in 2021]
[ Fujian Green Pine Co.Ltd(300132) : Announcement on the acquisition of utility model patents by wholly-owned subsidiaries]
Risk statement
The epidemic situation is repeated, the consumer demand is lower than expected, and the industry competition is intensified.
